These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 15709299)

  • 1. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

  • 2. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 3. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 5. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 6. A fair deal for the future: flexibilities under TRIPS.
    So AD
    Bull World Health Organ; 2004 Nov; 82(11):813. PubMed ID: 15640914
    [No Abstract]   [Full Text] [Related]  

  • 7. [The world population does not have the drugs it needs. WHO report recommends more stringent control of the drug industry].
    Asplund K
    Lakartidningen; 2005 Feb 14-20; 102(7):450-1. PubMed ID: 15768693
    [No Abstract]   [Full Text] [Related]  

  • 8. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 9. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 10. World pharmaceutical developments.
    Bale H
    World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
    [No Abstract]   [Full Text] [Related]  

  • 11. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
    Curti AM
    Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
    [No Abstract]   [Full Text] [Related]  

  • 12. The responsibility of research universities to promote access to essential medicines.
    't Hoen EF
    Yale J Health Policy Law Ethics; 2003; 3(2):293-300. PubMed ID: 14577145
    [No Abstract]   [Full Text] [Related]  

  • 13. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of India's new patents law 2005: a physician's perspective.
    Lele RD
    J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
    [No Abstract]   [Full Text] [Related]  

  • 15. Reprivatizing pharmaceutical supplies in Africa.
    Turshen M
    J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are rich nations up for drug reform?
    Check E
    Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
    [No Abstract]   [Full Text] [Related]  

  • 17. Access to essential drugs, human rights and global justice.
    Shalev C
    Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 20. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 38.